2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

Authors:
Banach M; Surma S; Toth PP; endorsed by the International Lipid Expert Panel (ILEP).

Journal:
Arch Med Sci

Publication Year: 2023

DOI:
10.5114/aoms/174743

PMCID:
PMC10696981

PMID:
38058712

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Arch Med Sci

Abbreviation: Arch Med Sci

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine, General & Internal

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Atypical presentation of Lyme disease.
Jarosińska A; Pilśniak A; Cieśla-Fuławka A and 3 more (2024) - Transparency Score: 2/6
Cuproptosis-related genes are involved in immunodeficiency following ischemic stroke.
Jinshi L; Cong Y; Liang S and 2 more (2024) - Transparency Score: 3/6
Efficacy of ornidazole for pericoronitis: a meta-analysis and systematic review.
Du R; Ba K; Yang Y and 2 more (2024) - Transparency Score: 2/6
Interleukins: pathophysiological role in acute pancreatitis.
Rafaqat S; Patoulias D; Behnoush AH and 2 more (2024) - Transparency Score: 3/6
Level of basic hope and symptoms of anxiety and depression in women after miscarriage.
Białek K; Sadowski M; Adamczyk-Gruszka O and 2 more (2024) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest M.B. – speakers bureau: Amgen, Daiichi Sankyo, KRKA, Pfizer, Polpharma, Mylan/Viatris, Novartis, Novo-Nordisk, Pfizer, Sanofi-Aventis, Teva, Zentiva; consultant to Adamed, Amgen, Daiichi Sankyo, Esperion, MSD, NewAmsterdam, Novartis, Novo-Nordisk, Sanofi-Aventis; Grants from Amgen, Daiichi Sankyo, Viatris, and Sanofi, CMO at the Nomi Biotech Corporation and Dairy Biotechnologies; S.S. – honoraria from Sandoz/Novartis; Pro.Med.; P.P.T. – speakers bureau for Amgen."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025